Head-To-Head Comparison: Sharps Technology (NASDAQ:STSS) vs. NeuroMetrix (NASDAQ:NURO)

NeuroMetrix (NASDAQ:NURO) and Sharps Technology (NASDAQ:STSS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Profitability

This table compares NeuroMetrix and Sharps Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroMetrix	-151.51%	-39.85%	-37.08%
Sharps Technology	N/A	-102.25%	-72.97%

Earnings & Valuation

This table compares NeuroMetrix and Sharps Technology’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroMetrix	$5.90 million	1.31	-$6.53 million	($6.30)	-0.61
Sharps Technology	N/A	N/A	-$9.84 million	N/A	N/A

NeuroMetrix has higher revenue and earnings than Sharps Technology.

Insider and Institutional Ownership

19.4% of NeuroMetrix shares are owned by institutional investors. Comparatively, 17.2% of Sharps Technology shares are owned by institutional investors. 7.3% of NeuroMetrix shares are owned by insiders. Comparatively, 14.1% of Sharps Technology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

NeuroMetrix has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for NeuroMetrix and Sharps Technology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroMetrix	0	0	0	0	N/A
Sharps Technology	0	0	0	0	N/A

Summary

NeuroMetrix beats Sharps Technology on 6 of the 8 factors compared between the two stocks.

About NeuroMetrix

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

About Sharps Technology

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.